Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716259 | 0.86 | CYP19A1 (0.54) | MAPTALDH1A1POLBHTTTSHR | |
| SCHEMBL561018 | 0.86 | CYP19A1 (0.48) | MAPTALDH1A1POLBHTTTSHR | |
| SCHEMBL6739273 | 0.82 | MAPT (0.47) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL7786787 | 0.81 | HTT (0.58) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL6742072 | 0.81 | MAPT (0.46) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL921902 | 0.81 | MAPT (0.46) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL7083788 | 0.80 | NPC1 (0.48) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL9464992 | 0.79 | ALDH1A1 (0.44) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL539064 | 0.79 | ALDH1A1 (0.60) | NPC1MAPTALDH1A1POLBHTT | |
| SCHEMBL65293 | 0.79 | CYP19A1 (0.62) | NPC1MAPTALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368129-B | Modified macrocyclic compounds | 拜耳医药股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-20180282346-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060167-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012005266-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学工業株式会社 (JP) | 2012-01-12 | — | — | WO | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| EP-1311480-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| EP-1311480-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| US-6433186-B1 | TREATMENT OF CONDITIONS WHERE INHIBITION OF THROMBIN IS REQUIRED (E.G. THROMBOSIS) OR AS ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | disclosed |
| US-20020068730-A1 | New amidino derivatives and their use as thormbin inhibitors | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | US | disclosed |
| WO-2002014270-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2000070083-A1 | ASSAY FOR MYELOSUPPRESSION BY FARNESYL TRANSFERASE INHIBITORS | MERCK & CO., INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6060038-A | Radiolabeled farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0981728-A2 | RADIOLABELED FARNESYL-PROTEIN TRANSFERASE INHIBITORS | Merck & Co., Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1999000654-A2 | RADIOLABELED FARNESYL-PROTEIN TRANSFERASE INHIBITORS | MERCK & CO., INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885MAPT 4573/4885ALDH1A1 1614/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | NPC1 2611/4885MAPT 4573/4885ALDH1A1 1614/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | NPC1 2227/4885MAPT 4486/4885ALDH1A1 2487/4885 |
| US-20180282346-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | PCNA, CYP11B2, CYP11B1 | NPC1 65/4885MAPT 4188/4885ALDH1A1 1293/4885 |
| US-20020068730-A1 | New amidino derivatives and their use as thormbin inhibitors | SERPINC1, SERPINE1, ADAMTS1 | NPC1 1994/4885MAPT 3616/4885ALDH1A1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.